InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-20.7%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
无可用的信号评分。
Explore the detailed record of transactions filed by Geffken Daniel E., 首席财务官. Officer active across 3 companies, notably Eloxx Pharmaceuticals, Inc.. Cumulatively, 4 filings have been logged. Split: 1 buy · 0 sell. Total volume traded: €32k. Activity tracked since 29 November 2021. The latest transaction was filed on 23 August 2023 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Geffken Daniel E.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
10,002 股Class A Common StockSEC:0001213900-24-015030:0
2,033 股0Common StockSEC:0001437749-23-024844:0
5,000 股0Common StockSEC:0001437749-22-014714:0
50,000 股@ US$0.72100.0% 占其流量Common StockSEC:0001415889-21-005600:0
标准退出：2022年2月27日 (T+90)
4 条申报中的 4 条
About Geffken Daniel E.
Daniel E. Geffken is the Interim Chief Financial Officer and Board Member at Eloxx Pharmaceuticals, Inc. and Windtree Therapeutics Inc. /DE/. He oversees the financial operations of both companies and is responsible for financial planning and risk management. His expertise is crucial in ensuring the financial health of these organizations.
